Grants for For profit organizations other than small businesses - Science and Technology

The overall goal of ProCON Global is to promote open, interoperable, reliable, and secure commercial undersea cable systems around the world. The project will provide technical assistance to key decision-makers, including policymakers, regulators, and technology companies in emerging economies, to promote evaluation processes and investment in secure and trusted vendors when establishing undersea cable network supply chains. Technology companies include telecommunications operators/carriers, major technology and security firms, innovators, and content and cloud providers.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Level 3. Funding Levels 1, 2, and 4 are available under other program announcements (HT942524BCRPBTA12 for Levels 1 and 2 and HT942524BCRPBTA4 for Level 4). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcements before submitting the pre-application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement:Funding Level 3: Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. If the proposed research would ultimately require U.S. Food and Drug Administration (FDA) involvement, applications must demonstrate availability of, and access to, clinical reagents (e.g., therapeutic molecules) and patient population(s). Applications must state a realistic timeline for near-term clinical investigation. Small-scale clinical trials (e.g., first in human, phase 1/1b) may be appropriate.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Level 3 applications unless they are clearly addressing distinct research questions. Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most or all of the experiments and analyses do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Level 3 should not exceed $4M for applications with a single PI or $5M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.95M to fund approximately two BCRP Breakthrough Award Level 3 applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports various organizations in Maine to develop and implement projects that expand affordable housing options and workforce housing through community planning and collaboration.

This funding opportunity supports research projects that use genome editing techniques to explore the genetic factors contributing to substance use disorders, encouraging diverse organizations to participate in advancing addiction science.

The Equip Harlingen grant program, offered by the Harlingen Economic Development Corporation (EDC), is a small business matching grant designed to provide financial assistance of up to $3,000 for new equipment purchases. This program is rooted in the EDC's mission to foster economic development within the City of Harlingen. By supporting businesses in expanding their production capabilities, the grant directly aligns with the foundation's strategic priority of stimulating economic activity and promoting job retention and creation. The underlying theory of change is that direct investment in local businesses' operational capacity will lead to increased production, sales, and ultimately, a more robust local economy with sustained employment opportunities. The primary target beneficiaries of the Equip Harlingen grant are for-profit commercial businesses located within the city limits of Harlingen, TX. Specifically, the program targets businesses that have been operational for at least one full year, occupy commercial space, and have fewer than 20 employees. This focus aims to bolster the small to medium-sized business sector, which is often a significant driver of local economies. National chains or franchises with more than three locations, and establishments with more than two locations, are explicitly excluded to ensure the benefits are concentrated on local, independent businesses. The program's core priorities and focuses revolve around supporting businesses in increasing production, expanding operations, and generating more sales through the acquisition of new equipment. Eligible expenses are strictly defined as new equipment under warranty that will directly enable these growth objectives, such as stoves, ovens, lathes, and tooling machines. The emphasis is on equipment that is essential for the creation of more products, indicating a clear focus on manufacturing, culinary, and other production-oriented businesses. The expected outcomes of the Equip Harlingen grant include the retention and creation of jobs within business enterprises in the City of Harlingen, leading to further economic stimulation. Measurable results are tied to the financial assistance provided, which is 50% of incurred equipment costs, not exceeding $3,000. While not explicitly stated as metrics, the program's success would likely be measured by the number of businesses supported, the direct increase in production capacity reported by recipients, and ultimately, the impact on local employment figures and sales tax generation. The requirement for applicants to generate local sales taxes reinforces the program's aim to contribute to the city's overall economic health.

This grant provides $1 million to a qualified nonprofit or educational institution in California to develop a project aimed at improving health outcomes and reducing disparities for low-income and marginalized communities in San Diego and Imperial Counties.

This grant provides funding to established and early-career biomedical researchers in Arizona to advance innovative health research that improves healthcare outcomes and stimulates the local economy.

This program provides matching funds to Nebraska businesses collaborating with local colleges or universities on research and development projects that create or improve products and processes to boost revenue.

This funding opportunity supports researchers and innovators developing groundbreaking technologies to reduce reliance on critical minerals in clean energy solutions, promoting sustainable alternatives and recycling methods.

This funding opportunity provides financial support to medical examiner and coroner offices for accreditation and to develop forensic pathology fellowships, addressing workforce shortages and improving death investigation standards nationwide.

This grant provides funding and resources to early-stage ag-tech businesses in Kentucky to develop and market innovative solutions that enhance the agricultural industry.

This funding opportunity provides financial support for research and statistical analysis related to crime and victimization, primarily aimed at enhancing the National Crime Victimization Survey and its methodologies.

This funding opportunity supports a variety of organizations in California to develop and implement safer, sustainable pest management practices that protect public health and the environment while promoting economic vitality.

The anticipated funding opportunity announcement (FOA) aims to support research and development projects under the Vehicle Technologies Office (VTO). The goals include the demonstration of smart charge management for electric vehicles, improvement of 12-volt lead-acid batteries for safety-critical electric vehicle applications, development of strategies to reduce the likelihood of cascading effects of electric vehicle fires, reduction in battery electrode, cell, and pack manufacturing costs, advancement of silicon-based anodes for lithium-ion batteries, and development of high-energy density conversion cathodes. The FOA emphasizes advancing equity, addressing the climate crisis, and achieving net-zero emissions by 2050. Eligible applicants are encouraged to include underrepresented groups and underserved communities in their project teams. The FOA will fund activities related to electric vehicle (EV) technologies, focusing on areas such as smart charge management, safety improvements in EV batteries, cost reduction in battery manufacturing, and the development of advanced battery materials. The Department of Energy aims to drive innovation in clean energy technologies, ensuring environmental justice and inclusion. Specific areas of interest include wide-scale demonstrations of smart charge management, enhancement of safety-critical 12-volt lead-acid batteries, reduction of cascading effects of battery fires, cost reduction in battery manufacturing, and the development of high-energy-density battery components.

The COVID-19 Relief – Supporting Elm and Main (SEAM) program will provide financial assistance to the community revitalization organizations dedicated to community and economic development in older and historic downtowns, commercial districts, and neighborhoods according to the principles of the Elm Street and Main Street Approaches. The program, supported by Keystone Communities funding, is intended to assist Elm Street and Main Street organizations that have been economically impacted by COVID-19. Financial Info: The COVID-19 Relief – Supporting Elm and Main (SEAM) program will provide financial assistance to the community revitalization organizations dedicated to community and economic development in older and historic downtowns, commercial districts, and neighborhoods according to the principles of the Elm Street and Main Street Approaches. The program, supported by Keystone Communities funding, is intended to assist Elm Street and Main Street organizations that have been economically impacted by COVID-19.

This program provides financial assistance to small business and commercial property owners in Jackson, Mississippi, to improve the appearance of their buildings and attract more customers and investors.

This grant provides funding for researchers to conduct innovative studies on ovarian cancer, focusing on impactful solutions that benefit patients and their families.

This funding opportunity provides financial support for projects that conserve and improve natural resources, targeting municipalities, nonprofits, schools, and private property owners in Hennepin County.

The ARP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ASD. Applications are strongly encouraged to address one of the FY24 ARP Clinical Trial Award Areas of Interest. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Research funded by the FY24 ARP should be responsive to the needs of people with ASD, their families, and/or caregivers. Researchers are therefore encouraged to establish and utilize effective collaborations and partnerships with community members to maximize the impact potential of the proposed research.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.

This initiative provides financial support to early-stage climate technology startups in Massachusetts to help them develop their innovations and achieve commercial success in the clean energy sector.